About: The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
Creator	Bayat, Babak Collignon, Sylvie Fortpied, Juliette Lemoine, Dominique Moniotte, Nicolas Renaud, Frédéric
Source	PMC
abstract	BACKGROUND: Developing thermostable vaccines is a challenge for pharmaceutical companies due to the inherent instability of biological molecules in aqueous solution. The problem is even more stringent in regions subjected to high temperatures in which protective cold chain is difficult to maintain due to a lack of infrastructure. Here, a simple, cost-effective solution to increase the thermostability of the malaria candidate vaccine RTS,S/AS01 is described. This vaccine currently needs to be stored between 2 and 8 °C due to the sensitivity of liquid AS01 to higher temperatures. The strategy was to increase thermostability by co-lyophilizing the RTS,S antigen and AS01. METHODS: Co-lyophilization was achieved in a solution containing 5% sucrose, 10 mM potassium phosphate and 0.0312% polysorbate 80 at pH 6.1. The physicho-chemical characteristics and immunogenic properties of the resulting solid product, called CL-vac, fresh or stored at high temperature, were compared to those of the candidate RTS,S/AS01. RESULTS: CL-vac proved to be acceptable in terms of visual appearance and physico-chemical characteristics. The structural integrity of both RTS,S and AS01 within CL-vac and its equivalence to the RTS,S/AS01 candidate vaccine were shown. Further, the stability of CL-vac was demonstrated for storage periods including 1 year at 4 °C, 1 year at 30 °C, and up to 6 months at 37 °C. In addition, CL-vac could withstand a heat excursion consisting of 1 month at 45 °C after storage for 1 year at 30 °C. Equivalence and stability were demonstrated by the various analytical tools and the immunogenicity of the samples after storage was also demonstrated in mice. CONCLUSIONS: In conclusion, the co-lyophilization process appeared as a promising approach to increase RTS/AS01 vaccine thermostability.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1186/s12936-020-03253-1
has license	cc-by
sha1sum (hex)	5776d6f6e4ccaf2538ed3cccb499066172221758
schema:url	https://doi.org/10.1186/s12936-020-03253-1
resource representing a document's title	The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
has PubMed Central identifier	PMC7276967
schema:publication	Malar J
resource representing a document's body	covid:5776d6f6e4ccaf2538ed3cccb499066172221758#body_text
is schema:about of	named entity 'problem' named entity 'strategy' named entity 'thermostability' named entity 'COLD CHAIN' named entity 'REGIONS' named entity 'COST' named entity 'TO MAINTAIN' covid:arg/5776d6f6e4ccaf2538ed3cccb499066172221758 named entity 'higher' named entity 'inherent' named entity 'antigen' named entity 'fluorescence' named entity 'QS-21' named entity 'immunogenic' named entity 'HBsAg' named entity 'vaccine' named entity 'phosphotungstate' named entity 'antigen' named entity 'dry nitrogen' named entity 'HBsAg' named entity 'QS-21' named entity 'antigen' named entity 'phase III' named entity 'RTS,S' named entity 'elution' named entity 'vial' named entity 'adjuvant' named entity 'HBsAg' named entity 'TMB' named entity 'NaCl' named entity 'Cold chain' named entity 'CSP' named entity 'negative staining' named entity 'serum' named entity 'serum' named entity 'vaccine' named entity 'carbon-coated' named entity 'malaria' named entity 'derivatization' named entity 'immunogenic' named entity 'HBsAg' named entity 'vial' named entity 'negative staining' named entity 'SDS-PAGE' named entity 'ANOVA' named entity 'T-cell' named entity 'RTS,S' named entity 'vial' named entity 'CSP' named entity 'vaccine' named entity 'trehalose' named entity 'biological molecules' named entity 'lyophilization' named entity 'CD4' named entity 'liquid form' named entity 'room temperature' named entity 'BSA' named entity 'hydrolysis' named entity 'reference group' named entity 'hydrolysis' named entity 'dithiothreitol' named entity 'RTS,S' named entity 'immunogenic' named entity 'RTS,S' named entity 'potency' named entity 'PBS' named entity 'liposome' named entity 'polystyrene' named entity 'antibody response' named entity 'recombinant fusion protein' named entity 'viscosity' named entity 'SEC' named entity 'sucrose' named entity 'RTS,S' named entity 'QS-21' named entity 'antibody' named entity 'Invitrogen' named entity 'vial'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software